Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Adapalene

Drug Profile

Adapalene

Alternative Names: CD-271; Differin Gel 0.1%; Differin Gel 0.3%; Differin Lotion 0.1%; Differin XP

Latest Information Update: 30 Aug 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Galderma
  • Class Anti-inflammatories; Antiacnes; Keratolytics; Naphthalenes; Retinoids; Small molecules
  • Mechanism of Action Retinoic acid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acne vulgaris
  • Phase III Photodamage
  • Discontinued Multiple sclerosis

Most Recent Events

  • 13 Apr 2017 Discontinued - Phase-III for Photodamage in USA (Topical)
  • 17 Nov 2016 Maruho plans a open label, randomised trial for Acne vulgaris (Combination therapy, In adolescents, In adults) in Japan (UMIN000024874)
  • 08 Jul 2016 Adapalene (Topical, gel,0.1%) has been designated as an Over-the-counter (OTC) product in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top